無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の非アルコール性脂肪性肝炎(NASH)治療薬および診断市場:パイプライン治療薬、診断技術、治療法、地域別 - 成長、動向、予測(2018年〜2023年)

Global Nonalcoholic Steatohepatitis Therapeutics and Diagnostics Market - Segmented by Pipeline Therapeutics, Diagnostic Techniques, Treatment Therapies, and Geography - Growth, Trends, and Forecast (2018 - 2023)

発行 Mordor Intelligence LLP 商品コード 649745
出版日 ページ情報 英文 108 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
世界の非アルコール性脂肪性肝炎(NASH)治療薬および診断市場:パイプライン治療薬、診断技術、治療法、地域別 - 成長、動向、予測(2018年〜2023年) Global Nonalcoholic Steatohepatitis Therapeutics and Diagnostics Market - Segmented by Pipeline Therapeutics, Diagnostic Techniques, Treatment Therapies, and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日: 2018年05月15日 ページ情報: 英文 108 Pages
概要

世界の非アルコール性脂肪性肝炎(NASH)治療薬および診断市場は、調査期間の2018年から2023年にかけて25.0%のCAGRで推移することが予測されています。糖尿病および肥満症の有病率の上昇や、研究開発への投資増大などによって、当市場の成長が促進されています。地域別では、新たな医療技術の導入率が高く、医療インフラが整備され研究開発が盛んな北米地域が最大市場として台頭しています。

当レポートでは、世界の非アルコール性脂肪性肝炎(NASH)市場を調査し、市場の概要、技術・用途・地域別の市場動向、市場規模の推移と予測、成長要因・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 市場のダイナミクス

  • 成長要因
    • NASH治療薬のた有望なパイプライン
    • 世界的な糖尿病および肥満症の罹患率の上昇
    • 新たなバイオマーカー技術の登場と肝生検技術の向上
  • 阻害要因
    • 非アルコール性脂肪性肝疾患(NAFLD)に対する有効な診断法の欠如
    • 治療分野における技術進歩の停滞
  • 市場機会
  • 主な課題

第7章 非アルコール性脂肪性肝炎(NASH)市場:セグメント別

  • パイプライン治療薬別
    • 第III相試験
      • オベチコール酸(OCA)
      • アラムコル(アラキジルアミドコラン酸)
      • サログリタザル
      • エラフィブラノール
      • その他
  • 診断技術別
    • イメージング
    • 肝生検
    • バイオマーカー診断
    • その他
  • 治療法別
    • 薬物療法
    • インスリン抵抗性改善治療
    • 抗サイトカイン療法
    • 外科手術
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • 合併・買収分析
  • 合意・提携・協力
  • 新製品の上市

第9章 主要企業

  • AstraZeneca PLC
  • Conatus Pharmaceuticals, Inc.
  • Enzo Biochem, Inc.
  • Galmed Pharmaceuticals Ltd
  • Genfit Corp.
  • Gilead
  • Horizon Pharma PLC
  • Immuron
  • Intercept Pharmaceuticals, Inc.
  • Novo Nordisk A/S

第10章 市場の将来展望

第11章 免責事項

目次
Product Code: 60469

The global nonalcoholic steatohepatitis (NASH) therapeutics and Diagnostics market is expected to register a CAGR of 25.0% during the forecast period of 2018 -2023. This market is boosted by the growing prevalence of diabetes and obesity, and high investments for research and development, which leads to rising demand for NASH and others nonalcoholic fatty liver diseases (NAFLD) therapies in the market. As per the regional analysis, the well-established healthcare infrastructure with the high adoption rate of new technologies and increasing research activities, makes North America dominate this market.

Rising Prevalence of Diabetic and Obese Population Globally

The increasing global prevalence of diabetic and obese population particularly in the developed markets is expected to raise the NASH therapeutics and diagnostics market. An estimated 5-20% of the population accounting for nearly 15 million, shows the prevalence of NASH consuming fatty acids diet in the United States, which is driven by obesity and diabetes. In the United Kingdom, as per the Diabetes Community, 2015, over four million people were diagnosed with diabetes which represented 6% of the United Kingdom's population, i.e., one in every 16. With that, the United Kingdom had the fifth highest rate of obesity in Europe in 2015, with nearly 25% of the population having body mass index of 30 or more. A similar trend or higher could be found in several developed countries, which raises the demand for NASH therapeutics and diagnostics market.

Other factors driving this market are the lucrative pipeline for NASH therapeutics and emergence of novel biomarkers and improvement in liver biopsy technologies.

Slow Advances in the Therapeutic Field

One of the primary hindrances for NASH therapeutics and diagnostics market is the slow advancements in the therapeutic field. According to an article published in 2015, in the Journal of Hepatology, there is no approved drug for NASH even after the 35 years of its formal description and 15 years of intense research worldwide. Although there are several drugs in the pipeline but the process of approving the drug to next phase has been slow. The wide range of multiple pathogenic mechanisms hinders the success rate of the drugs in clinical trials. Thus, restricting the growth of this market.

Another factor impeding this market is the lack of effective diagnostics for NAFLD.

North America to Dominate the Market

North America is set to dominate the market in the period from 2018 to 2023 for NASH therapeutics and diagnostics. The well-established healthcare infrastructure with high preference to research and development activities makes the United States a region with high opportunities for growth and long-term establishment for companies. With that, the large number of prevailing cases of high cholesterol and change in lifestyle plays a vital role in the growth of this market.

Key Developments in the Market

April 2018 - AstraZeneca licensed IONIS-AZ6-2.5-LRx, NASH drug from Ionis Pharmaceuticals, Inc. for USD 30 million.

December 2017 - NorthSea Therapeutics B.V. completed a EUR 25 million Series A funding for the development of icosabutate, an oral promising drug candidate for the treatment of NASH.

Major Players - ASTRAZENECA PLC, CONATUS PHARMACEUTICALS, INC., ENZO BIOCHEM, INC., GALMED PHARMACEUTICALS LTD, GENFIT CORP., GILEAD, HORIZON PHARMA PLC, IMMURON, INTERCEPT PHARMACEUTICALS, INC., AND NOVO NORDISK A/S, amongst others.

Reasons to Purchase the Report

Current and future of global nonalcoholic steatohepatitis therapeutics and diagnostics market outlook in the developed and emerging markets.

Analysis of various perspectives of the market with the help of Porter's Five Forces Analysis.

The segment that is expected to dominate the market.

Regions that are expected to witness the fastest growth during the forecast period.

Identify the latest developments, market shares, and strategies employed by the major market players.

3-month analyst support, along with the Market Estimate sheet (in Excel).

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Products and Services
    • 5.2.5 Competitive Rivalry

6. Market Dynamics

  • 6.1 Drivers
    • 6.1.1 Lucrative Pipeline for NASH Therapeutics
    • 6.1.2 Rising Prevalence of Diabetic and Obese Population Globally
    • 6.1.3 Emergence of Novel Biomarker Technologies and Improvement in Liver Biopsy Technologies
  • 6.2 Restraints
    • 6.2.1 Lack of Effective Diagnostics for Non Alcoholic Fatty Liver Disease (NAFLD)
    • 6.2.2 Slow Advances in the Therapeutic Field
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Therapeutics
    • 7.1.1 Phase III
      • 7.1.1.1 Obeticholic Acid (OCA)
      • 7.1.1.2 Aramchol (arachidyl amido cholanoic acid)
      • 7.1.1.3 Saroglitazar
      • 7.1.1.4 Elafibranor
      • 7.1.1.5 Others
  • 7.2 By Diagnostics Technqiues
    • 7.2.1 Imaging
      • 7.2.1.1 Ultrasonography (US)
      • 7.2.1.2 Computed Tomography (CT)
      • 7.2.1.3 Magnetic Resonance Imaging (MRI)
      • 7.2.1.4 Others
    • 7.2.2 Liver Biopsy
    • 7.2.3 Biomarker diagnostics
      • 7.2.3.1 Serum Biomarkers
      • 7.2.3.2 Hepatic Fibrosis Biomarkers
      • 7.2.3.3 Apoptosis Biomarkers
      • 7.2.3.4 Oxidative Stress Biomarkers
      • 7.2.3.5 Others
    • 7.2.4 Other Diagnostics
  • 7.3 By Treatment Therapies
    • 7.3.1 Pharmacologic Therapy
    • 7.3.2 Steatosis/insulin Resistance
    • 7.3.3 Anti-Cytokines
    • 7.3.4 Surgical Interventions
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States
      • 7.4.1.2 Canada
      • 7.4.1.3 Mexico
      • 7.4.1.4 Rest of North America
    • 7.4.2 Europe
      • 7.4.2.1 France
      • 7.4.2.2 Germany
      • 7.4.2.3 United Kingdom
      • 7.4.2.4 Italy
      • 7.4.2.5 Spain
      • 7.4.2.6 Rest of Europe
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China
      • 7.4.3.2 Japan
      • 7.4.3.3 India
      • 7.4.3.4 Australia
      • 7.4.3.5 South Korea
      • 7.4.3.6 Rest of Asia-Pacific
    • 7.4.4 Middle East & Africa
      • 7.4.4.1 GCC
      • 7.4.4.2 South Africa
      • 7.4.4.3 Rest of Middle East & Africa
    • 7.4.5 South America
      • 7.4.5.1 Brazil
      • 7.4.5.2 Argentina
      • 7.4.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 AstraZeneca PLC
  • 9.2 Conatus Pharmaceuticals, Inc.
  • 9.3 Enzo Biochem, Inc.
  • 9.4 Galmed Pharmaceuticals Ltd
  • 9.5 Genfit Corp.
  • 9.6 Gilead
  • 9.7 Horizon Pharma PLC
  • 9.8 Immuron
  • 9.9 Intercept Pharmaceuticals, Inc.
  • 9.10 Novo Nordisk A/S

List not Exhaustive

10. Future of the Market

11. Disclaimer

Back to Top